Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.

[1]  D. Matei,et al.  A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum‐resistant, epithelial ovarian cancer , 2010, Cancer.

[2]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[3]  Robert S Illingworth,et al.  CpG islands – ‘A rough guide’ , 2009, FEBS letters.

[4]  Robert C. Bast,et al.  The biology of ovarian cancer: new opportunities for translation , 2009, Nature Reviews Cancer.

[5]  K. Nephew,et al.  A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer. , 2009, Neoplasia.

[6]  Robert Brown,et al.  The promises and pitfalls of epigenetic therapies in solid tumours. , 2009, European journal of cancer.

[7]  A. Toland,et al.  Methylation not a frequent “second hit” in tumors with germline BRCA mutations , 2009, Familial Cancer.

[8]  P. Finn,et al.  Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo , 2009, British Journal of Cancer.

[9]  Timothy A. Yap,et al.  Beyond chemotherapy: targeted therapies in ovarian cancer , 2009, Nature Reviews Cancer.

[10]  Wei Hu,et al.  Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. , 2009, American journal of obstetrics and gynecology.

[11]  S. Mok,et al.  Aberrant promoter methylation of SPARC in ovarian cancer. , 2009, Neoplasia.

[12]  H. Su,et al.  An epigenetic marker panel for screening and prognostic prediction of ovarian cancer , 2009, International journal of cancer.

[13]  Meng Li,et al.  Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer , 2009, BMC Medical Genomics.

[14]  Sun Mi Park,et al.  MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death , 2008, Oncogene.

[15]  Rekha Rao,et al.  Cotreatment with Vorinostat Enhances Activity of MK-0457 (VX-680) against Acute and Chronic Myelogenous Leukemia Cells , 2008, Clinical Cancer Research.

[16]  Huaxia Qin,et al.  Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer. , 2008, Neoplasia.

[17]  Gordon B Mills,et al.  Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers , 2008, Molecular carcinogenesis.

[18]  Martin Widschwendter,et al.  HOXA11 DNA methylation—A novel prognostic biomarker in ovarian cancer , 2008, International journal of cancer.

[19]  A. Mutirangura,et al.  LINE‐ 1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer , 2008, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[20]  S. Hirohashi,et al.  Frequent inactivation of a putative tumor suppressor, angiopoietin-like protein 2, in ovarian cancer. , 2008, Cancer research.

[21]  R. Bast,et al.  A phase IIa study of a sequential regimen using azacitidine to reverse platinum resistance to carboplatin in patients with platinum resistant or refractory epithelial ovarian cancer , 2008 .

[22]  J. O'Brien,et al.  Evaluation of the In vitro and In vivo Antitumor Activity of Histone Deacetylase Inhibitors for the Therapy of Retinoblastoma , 2008, Clinical Cancer Research.

[23]  S. Modesitt,et al.  A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. , 2008, Gynecologic oncology.

[24]  Zhen Lu,et al.  Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down‐regulated in human ovarian cancers by loss of heterozygosity and promoter methylation , 2008, Cancer.

[25]  Susan J Clark,et al.  DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. , 2008, Gynecologic oncology.

[26]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[27]  A. Godwin,et al.  Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. , 2008, Cancer research.

[28]  Robert Brown,et al.  A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors , 2008, Clinical Cancer Research.

[29]  P. Pandolfi,et al.  Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes , 2008, Clinical Cancer Research.

[30]  George S Watts,et al.  DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage , 2008, BMC Medical Genomics.

[31]  P. Spellman,et al.  Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities , 2008, BMC Cancer.

[32]  Andreas Schätzlein,et al.  Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Kevin Camphausen,et al.  Inhibition of histone deacetylation: a strategy for tumor radiosensitization. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  S. Hirohashi,et al.  Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer. , 2007, Cancer research.

[35]  J. Chien,et al.  Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance , 2007, Oncogene.

[36]  P. Dent,et al.  Synergistic Interactions between Vorinostat and Sorafenib in Chronic Myelogenous Leukemia Cells Involve Mcl-1 and p21CIP1 Down-Regulation , 2007, Clinical Cancer Research.

[37]  M. Gregor,et al.  Epigenetic combination therapy as a tumor‐selective treatment approach for hepatocellular carcinoma , 2007, Cancer.

[38]  G. Jayson,et al.  Heparan sulphate synthetic and editing enzymes in ovarian cancer , 2007, British Journal of Cancer.

[39]  Chun-Min Lo,et al.  Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin. , 2007, Neoplasia.

[40]  R. Ozols,et al.  The management of recurrent ovarian cancer. , 2007, Seminars in oncology.

[41]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[42]  E. Lander,et al.  The Mammalian Epigenome , 2007, Cell.

[43]  K. Odunsi,et al.  DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. , 2007, Cancer immunity.

[44]  C. Croce,et al.  MicroRNA signatures in human ovarian cancer. , 2007, Cancer research.

[45]  Ming Zhao,et al.  Phase I Study of Decitabine-Mediated Gene Expression in Patients with Cancers Involving the Lungs, Esophagus, or Pleura , 2006, Clinical Cancer Research.

[46]  C. Caslini,et al.  Histone modifications silence the GATA transcription factor genes in ovarian cancer , 2006, Oncogene.

[47]  R. Larson,et al.  Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  P. Houghton,et al.  Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  M. Sehested,et al.  Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies , 2006, Molecular Cancer Therapeutics.

[50]  L. Hongmei,et al.  Clinical Evaluation of E-cadherin Expression and its Regulation Mechanism in Epithelial Ovarian Cancer , 2006, Clinical & Experimental Metastasis.

[51]  J. Kotarski,et al.  The role of CpG islands hypomethylation and abnormal expression of neuronal protein synuclein-gamma (SNCG) in ovarian cancer. , 2006, Neuro endocrinology letters.

[52]  Annie P. Moseman,et al.  Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. , 2006, Cancer research.

[53]  Sandya Liyanarachchi,et al.  Prognostic DNA Methylation Biomarkers in Ovarian Cancer , 2006, Clinical Cancer Research.

[54]  Christian B. Woods,et al.  Quantitative analysis of associations between DNA hypermethylation, hypomethylation, and DNMT RNA levels in ovarian tumors , 2006, Oncogene.

[55]  John M Bennett,et al.  Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.

[56]  A. Berchuck,et al.  Frequent IGF2/H19 Domain Epigenetic Alterations and Elevated IGF2 Expression in Epithelial Ovarian Cancer , 2006, Molecular Cancer Research.

[57]  A. Zelenetz,et al.  Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  W. V. Overveld,et al.  Decitabine: a historical review of the development of an epigenetic drug , 2006, Annals of Hematology.

[59]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[60]  V. P. Collins,et al.  Differential expression of selected histone modifier genes in human solid cancers , 2006, BMC Genomics.

[61]  E. Valls,et al.  Role of Histone Modifications in Marking and Activating Genes through Mitosis* , 2005, Journal of Biological Chemistry.

[62]  Robert Brown,et al.  Pharmacodynamic effects in patients treated with 6 hour infusion of the demethylating agent 5-aza-2 ' deoxycytidine (decitabine) , 2005 .

[63]  Christian B. Woods,et al.  Analysis of repetitive element DNA methylation by MethyLight , 2005, Nucleic acids research.

[64]  H. LaVoie.  Epigenetic control of ovarian function: The emerging role of histone modifications , 2005, Molecular and Cellular Endocrinology.

[65]  Frank Lyko,et al.  DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. , 2005, Journal of the National Cancer Institute.

[66]  J. Kuykendall.  5-Azacytidine and Decitabine Monotherapies of Myelodysplastic Disorders , 2005, The Annals of pharmacotherapy.

[67]  M. Toyota,et al.  Epigenetic changes in solid and hematopoietic tumors. , 2005, Seminars in oncology.

[68]  Pearlly Yan,et al.  Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer , 2005, Molecular Cancer Therapeutics.

[69]  J. Issa,et al.  Decitabine dosing schedules. , 2005, Seminars in hematology.

[70]  C. Der,et al.  Ras-mediated Loss of the Pro-apoptotic Response Protein Par-4 Is Mediated by DNA Hypermethylation through Raf-independent and Raf-dependent Signaling Cascades in Epithelial Cells* , 2005, Journal of Biological Chemistry.

[71]  J. Issa,et al.  Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  L. Schwartz,et al.  Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  David A Jones,et al.  Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  J. Issa,et al.  Decitabine low-dose schedule (100 mg/m2/course) in myelodysplastic syndrome (MDS). Comparison of 3 different dose schedules , 2005 .

[75]  Robert Brown,et al.  Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. , 2005, Gynecologic oncology.

[76]  K. Nephew,et al.  New anti-cancer strategies: epigenetic therapies and biomarkers. , 2005, Frontiers in bioscience : a journal and virtual library.

[77]  M. Ehrlich.  DNA methylation and cancer-associated genetic instability. , 2005, Advances in experimental medicine and biology.

[78]  T. Hamilton,et al.  Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer. , 2004, Gynecologic oncology.

[79]  Robert Brown,et al.  The epigenetics of ovarian cancer drug resistance and resensitization. , 2004, American journal of obstetrics and gynecology.

[80]  Paul Cairns,et al.  Tumor Cell-Specific BRCA1 and RASSF1A Hypermethylation in Serum, Plasma, and Peritoneal Fluid from Ovarian Cancer Patients , 2004, Cancer Research.

[81]  J. Roth,et al.  5-aza-2′-deoxycytidine upregulates caspase-9 expression cooperating with p53-induced apoptosis in human lung cancer cells , 2004, Oncogene.

[82]  Robert Brown,et al.  The Acquisition of hMLH1 Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients , 2004, Clinical Cancer Research.

[83]  Peter W. Laird,et al.  DNA Hypomethylation and Ovarian Cancer Biology , 2004, Cancer Research.

[84]  M. Toyota,et al.  Epigenetic Inactivation of TMS1/ASC in Ovarian Cancer , 2004, Clinical Cancer Research.

[85]  Huidong Shi,et al.  Double RNA interference of DNMT3b and DNMT1 enhances DNA demethylation and gene reactivation. , 2003, Cancer research.

[86]  P. Finn,et al.  Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. , 2003, Molecular cancer therapeutics.

[87]  P. Bates,et al.  OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer , 2003, Nature Genetics.

[88]  P. Laird,et al.  Phase I trial of continuous infusion 5-aza-2′-deoxycytidine , 2003, Cancer Chemotherapy and Pharmacology.

[89]  M. Parmar,et al.  First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence , 2002, British Journal of Cancer.

[90]  R. Buller,et al.  Inactivation of BRCA1 and BRCA2 in ovarian cancer. , 2002, Journal of the National Cancer Institute.

[91]  David A Jones,et al.  Reactivating the expression of methylation silenced genes in human cancer , 2002, Oncogene.

[92]  M. Ehrlich,et al.  DNA methylation in cancer: too much, but also too little , 2002, Oncogene.

[93]  Tim Hui-Ming Huang,et al.  Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[94]  J. Holland,et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  H. Kantarjian.  Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  J. Holland,et al.  Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  J. Weber,et al.  Review of the clinical experience with 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumors. , 2002, Current opinion in investigational drugs.

[98]  L. Grochow,et al.  A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[99]  G. Chenevix-Trench,et al.  Reduced expression of intercellular adhesion molecule-1 in ovarian adenocarcinomas , 2001, British Journal of Cancer.

[100]  K. Nephew,et al.  DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells. , 2001, Gynecologic oncology.

[101]  K. Nephew,et al.  DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. , 2001, Gynecologic oncology.

[102]  R C Coombes,et al.  Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[103]  Robert Brown,et al.  Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. , 2001, The American journal of pathology.

[104]  J. Sludden,et al.  Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. , 2000, Cancer research.

[105]  R. L. Baldwin,et al.  BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. , 2000, Cancer research.

[106]  P. Marks,et al.  Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[107]  M. Lübbert,et al.  Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  G. Strathdee,et al.  A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer , 1999, Oncogene.

[109]  M. Ehrlich,et al.  Satellite DNA hypomethylation vs. overall genomic hypomethylation in ovarian epithelial tumors of different malignant potential. , 1999, Mutation research.

[110]  T. Löning,et al.  p16/MTS1 inactivation in ovarian carcinomas: High frequency of reduced protein expression associated with hyper‐methylation or mutation in endometrioid and mucinous tumors , 1998, International journal of cancer.

[111]  S. Inoue,et al.  Role of the histone deacetylase complex in acute promyelocytic leukaemia , 1998, Nature.

[112]  P. Chiang,et al.  Apoptosis of L1210 Leukemia Cells Induced by 3-Deazaadenosine Analogs: Differential Expression of c-myc, NF-Kappa B and Molecular Events. , 1997, Journal of biomedical science.

[113]  Mimi C. Yu,et al.  Alterations in DNA methylation are early, but not initial, events in ovarian tumorigenesis. , 1997, British Journal of Cancer.

[114]  J. Blessing,et al.  A Phase II Study of Fazarabine in Patients with Advanced Ovarian Cancer A Gynecologic Oncology Group Study , 1995, American journal of clinical oncology.

[115]  M. McKay,et al.  Cancer of the ovary. , 1994, The New England journal of medicine.

[116]  R. Willemze,et al.  Preliminary results with 5-aza-2'-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group. , 1993, Leukemia.

[117]  V. Attadia.  Effects of 5-aza-2'-deoxycytidine on differentiation and oncogene expression in the human monoblastic leukemia cell line U-937. , 1993, Leukemia.

[118]  T. Masuda,et al.  Epigenetic modification is involved in aberrant expression of class III β-tubulin, TUBB3, in ovarian cancer cells , 1992 .

[119]  T. Masuda,et al.  Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells. , 1992, International journal of oncology.

[120]  J. Abbruzzese,et al.  Synergistic cytotoxicity using 2'-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells. , 1990, Cancer research.

[121]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[122]  A. Fusco,et al.  5-Aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. , 1984, Blood.

[123]  M. Ehrlich,et al.  The 5-methylcytosine content of DNA from human tumors. , 1983, Nucleic acids research.

[124]  Peter A. Jones,et al.  Cellular differentiation, cytidine analogs and DNA methylation , 1980, Cell.